Kento Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kento Kato has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Soyama
Department of Obstetrics and Gynecology, Takanohara Central Hospital
5 shared publications - Masashi Takano
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
5 shared publications - Morikazu Miyamoto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
5 shared publications - Hiroko Matsuura
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
3 shared publications - Kazuki Takasaki
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
3 shared publications - Kenichi Furuya
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
3 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Open AccessEstablishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- Open Access
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Cesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Open AccessCesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- 9 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 251
Basic Study of Ultrasound Hyperthermia Using Acrylic Guide
In recent years, electromagnetic wave hyperthermia and high intensity focused ultrasound (HIFU) treatment have been used as non-invasive tumor treatment methods. HIFU is a treatment method that cauterizes a tumor by focusing ultrasound waves from the outside of human body to a single point and raises the temperature near the focal point to a temperature of approximately 70 ° C or higher. On the other hand, electromagnetic wave hyperthermia is a method of treating cancerous tissues with electromagnetic wave power from 42 to 43 ° C for a certain period of time. Electromagnetic wave hyperthermia has a risk of undesirable heating near the electrodes. Since HIFU is done at high temperature, there is a risk of cauterizing healthy tissue. In addition, tissues with high acoustic impedance such as bones exist inside the human body, and ultrasound waves will be reflected and scattered. In this study, we focused on ultrasound hyperthermia which has the advantages of both of these treatment methods. In the proposed ultrasound hyperthermia treatment method, multiple transducers are used to superimpose ultrasound waves to heat the targeted area. As ultrasound waves are superimposed from multiple directions, the output of one transducer is low, and it is thought that abnormal heating unlikely occurs near the ultrasound source. Therefore, it is thought that the proposed method can be performed safely compared to HIFU and electromagnetic wave hyperthermia. In addition, in order to heat the affected area with ultrasound waves, it is necessary to irradiate the affected area linearly without diffusing the ultrasound waves. In the present study, a cylindrical acrylic guide was attached at the tip of the transducer, and the change of ultrasound intensity was examined with computer simulations and experiments. In the experiments, as shown in Figure 1 , a transducer with an acrylic guide was placed inside a water tank and moved by 0.5mm along the X direction to measure the ultrasound intensity. We also performed similar simulations and compared both results. From the computer simulations, the maximum sound pressure values were 300[MPa] without and 660[MPa] with the acrylic guide. Therefore, it can be seen that ultrasound intensity is about doubled when the guide is provided. In the experiments, the ultrasound intensity was 1.2[mV] without and 2.3[mV] with the guide, also it can be seen that the ultrasound intensity is approximately doubled. From these results, it was confirmed that the ultrasound intensity was high when using the acrylic guide. As a result, it is considered that by attaching an acrylic guide, ultrasound waves are irradiated linearly without diffusing, and it is possible to effectively heat the affected area. We are working on conducting experiments and simulations when ultrasound waves are superimposed using multiple transducers, and examining the results.
- 9 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 251
Basic Study of Ultrasound Hyperthermia Using Acrylic Guide
In recent years, electromagnetic wave hyperthermia and high intensity focused ultrasound (HIFU) treatment have been used as non-invasive tumor treatment methods. HIFU is a treatment method that cauterizes a tumor by focusing ultrasound waves from the outside of human body to a single point and raises the temperature near the focal point to a temperature of approximately 70 ° C or higher. On the other hand, electromagnetic wave hyperthermia is a method of treating cancerous tissues with electromagnetic wave power from 42 to 43 ° C for a certain period of time. Electromagnetic wave hyperthermia has a risk of undesirable heating near the electrodes. Since HIFU is done at high temperature, there is a risk of cauterizing healthy tissue. In addition, tissues with high acoustic impedance such as bones exist inside the human body, and ultrasound waves will be reflected and scattered. In this study, we focused on ultrasound hyperthermia which has the advantages of both of these treatment methods. In the proposed ultrasound hyperthermia treatment method, multiple transducers are used to superimpose ultrasound waves to heat the targeted area. As ultrasound waves are superimposed from multiple directions, the output of one transducer is low, and it is thought that abnormal heating unlikely occurs near the ultrasound source. Therefore, it is thought that the proposed method can be performed safely compared to HIFU and electromagnetic wave hyperthermia. In addition, in order to heat the affected area with ultrasound waves, it is necessary to irradiate the affected area linearly without diffusing the ultrasound waves. In the present study, a cylindrical acrylic guide was attached at the tip of the transducer, and the change of ultrasound intensity was examined with computer simulations and experiments. In the experiments, as shown in Figure 1 , a transducer with an acrylic guide was placed inside a water tank and moved by 0.5mm along the X direction to measure the ultrasound intensity. We also performed similar simulations and compared both results. From the computer simulations, the maximum sound pressure values were 300[MPa] without and 660[MPa] with the acrylic guide. Therefore, it can be seen that ultrasound intensity is about doubled when the guide is provided. In the experiments, the ultrasound intensity was 1.2[mV] without and 2.3[mV] with the guide, also it can be seen that the ultrasound intensity is approximately doubled. From these results, it was confirmed that the ultrasound intensity was high when using the acrylic guide. As a result, it is considered that by attaching an acrylic guide, ultrasound waves are irradiated linearly without diffusing, and it is possible to effectively heat the affected area. We are working on conducting experiments and simulations when ultrasound waves are superimposed using multiple transducers, and examining the results.
- 1 October 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , v240
Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
FMS-like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis, and FLT3-associated molecular alterations are an established predictor for the treatment with FLT3 inhibitors in acute myeloid leukemia. However, the oncogenic role of FLT3 amplification (amp) in patients (pts) with metastatic colorectal cancer (mCRC) has not yet been well established. Tumor tissue samples from 2,329 mCRC pts were sequenced using next-generation sequencing (NGS) with Oncomine Comprehensive Assay in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Clinicopathological features, co-altered genes, prognosis and regorafenib efficacy on FLT3 amp (defined as copy number ≥ 7.0) vs. non-FLT3 amp mCRC were investigated. Between Apr 2015 and Jun 2018, a total of 85 pts (3.6%) with mCRC with FLT3 amp were observed. There were no clear differences in baseline characteristics between pts with or without FLT3 amp. The enrichment of TP53 mutation in FLT3 amp mCRC was observed more frequently than non-FLT3 amp (74.1% vs. 64.7%, P = 0.08), but RAS mutation frequency was similar in both (48.2% vs. 42.8%, P = 0.31). In contrast, activating alterations in BRAF (1.1% vs. 7.1%, P = 0.053) and PIK3CA (1.1% vs 7.0%, P = 0.03) mutations were both less frequent in FLT3 amp vs. non-FLT3 amp mCRC. Median OS from 1st-line chemotherapy in FLT3 amp mCRC was significantly shorter than those in non-FLT3 amp (30.2 vs. 43.4 months, P = 0.002). Furthermore, in 20 pts receiving regorafenib, a multikinase inhibitor with a mild inhibitory activity of FLT3, the disease control rate (DCR) was higher in FLT3 amp mCRC pts (n = 7) compared with non-FLT3 amp (57.1% vs. 23.0 %, P = 0.13). FLT3 amp was associated with a significantly worse survival and a higher DCR from regorafenib, suggesting it has a distinct oncogenic role in mCRC. Further investigation of the oncogenic role of FLT3 amp in mCRC is warranted in clinical trials. UMIN000016344. SCRUM-Japan. 17 SCRUM-Japan Collaborating Pharmaceutical Companies, AMED, NCC. H. Taniguchi: Research grant / Funding (self): Takeda; Advisory / Consultancy: Chugai; Advisory / Consultancy: Taiho. T. Kato: Honoraria (self): Chugai Pharmaceutical; Advisory / Consultancy: Takeda; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Yakult Honsya. S. Yuki: Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bayer Yakuhin; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Pharma International; Speaker Bureau / Expert testimony: Daiichi Sankyo; Speaker Bureau / Expert testimony: Takeda Pharmaceutical; Speaker Bureau / Expert testimony: Eli Lilly Japan; Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Biopharma. T. Masuishi: Honoraria (self): Eli Lilly; Honoraria (self): Chugai Pharma; Honoraria (self): Merck Serono; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Yakult Honsya. K. Kato: Research grant / Funding (self): Shionogi; Research grant / Funding (self): Ono Pharmaceutical; Research grant / Funding (self): Merck Serono. N. Izawa: Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: Sanofi; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Bristol-Myers; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Serono. T. Moriwaki: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): Eisai; Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Serono; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Liliy Japan; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Ono Pharmaceutical. Y. Kagawa: Speaker Bureau / Expert testimony: Chugai; Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Sanofi; Speaker Bureau / Expert testimony: Taiho. W. Okamoto: Research grant / Funding (institution): MSD. Y. Nakamura: Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Taiho Pharmaceutical. K. Yamazaki: Honoraria (self): Daiichi Sankyo; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Eli Lilly; Honoraria (self): Merck Serono; Honoraria (self), Research grant / Funding (institution): Taiho Pharma; Honoraria (self): Bayer Yakuhin. T. Yoshino: Research grant / Funding (institution): Chugai pharma; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Sumitomo Dainippon pharma; Research grant / Funding (institution): Glaxo SmithKline. All other authors have declared no conflicts of interest.
- 1 October 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , v240
Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
FMS-like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis, and FLT3-associated molecular alterations are an established predictor for the treatment with FLT3 inhibitors in acute myeloid leukemia. However, the oncogenic role of FLT3 amplification (amp) in patients (pts) with metastatic colorectal cancer (mCRC) has not yet been well established. Tumor tissue samples from 2,329 mCRC pts were sequenced using next-generation sequencing (NGS) with Oncomine Comprehensive Assay in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Clinicopathological features, co-altered genes, prognosis and regorafenib efficacy on FLT3 amp (defined as copy number ≥ 7.0) vs. non-FLT3 amp mCRC were investigated. Between Apr 2015 and Jun 2018, a total of 85 pts (3.6%) with mCRC with FLT3 amp were observed. There were no clear differences in baseline characteristics between pts with or without FLT3 amp. The enrichment of TP53 mutation in FLT3 amp mCRC was observed more frequently than non-FLT3 amp (74.1% vs. 64.7%, P = 0.08), but RAS mutation frequency was similar in both (48.2% vs. 42.8%, P = 0.31). In contrast, activating alterations in BRAF (1.1% vs. 7.1%, P = 0.053) and PIK3CA (1.1% vs 7.0%, P = 0.03) mutations were both less frequent in FLT3 amp vs. non-FLT3 amp mCRC. Median OS from 1st-line chemotherapy in FLT3 amp mCRC was significantly shorter than those in non-FLT3 amp (30.2 vs. 43.4 months, P = 0.002). Furthermore, in 20 pts receiving regorafenib, a multikinase inhibitor with a mild inhibitory activity of FLT3, the disease control rate (DCR) was higher in FLT3 amp mCRC pts (n = 7) compared with non-FLT3 amp (57.1% vs. 23.0 %, P = 0.13). FLT3 amp was associated with a significantly worse survival and a higher DCR from regorafenib, suggesting it has a distinct oncogenic role in mCRC. Further investigation of the oncogenic role of FLT3 amp in mCRC is warranted in clinical trials. UMIN000016344. SCRUM-Japan. 17 SCRUM-Japan Collaborating Pharmaceutical Companies, AMED, NCC. H. Taniguchi: Research grant / Funding (self): Takeda; Advisory / Consultancy: Chugai; Advisory / Consultancy: Taiho. T. Kato: Honoraria (self): Chugai Pharmaceutical; Advisory / Consultancy: Takeda; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Yakult Honsya. S. Yuki: Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bayer Yakuhin; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Pharma International; Speaker Bureau / Expert testimony: Daiichi Sankyo; Speaker Bureau / Expert testimony: Takeda Pharmaceutical; Speaker Bureau / Expert testimony: Eli Lilly Japan; Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Biopharma. T. Masuishi: Honoraria (self): Eli Lilly; Honoraria (self): Chugai Pharma; Honoraria (self): Merck Serono; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Yakult Honsya. K. Kato: Research grant / Funding (self): Shionogi; Research grant / Funding (self): Ono Pharmaceutical; Research grant / Funding (self): Merck Serono. N. Izawa: Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: Sanofi; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Bristol-Myers; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Serono. T. Moriwaki: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): Eisai; Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Serono; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Liliy Japan; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Ono Pharmaceutical. Y. Kagawa: Speaker Bureau / Expert testimony: Chugai; Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Sanofi; Speaker Bureau / Expert testimony: Taiho. W. Okamoto: Research grant / Funding (institution): MSD. Y. Nakamura: Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Taiho Pharmaceutical. K. Yamazaki: Honoraria (self): Daiichi Sankyo; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Eli Lilly; Honoraria (self): Merck Serono; Honoraria (self), Research grant / Funding (institution): Taiho Pharma; Honoraria (self): Bayer Yakuhin. T. Yoshino: Research grant / Funding (institution): Chugai pharma; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Sumitomo Dainippon pharma; Research grant / Funding (institution): Glaxo SmithKline. All other authors have declared no conflicts of interest.
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- 22 November 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (12) , 201
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin
High-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed. The association between the change in HtrA2 and proteins associated with LATS1 in ovarian serous cancer cell lines after repeated treatment with cisplatin was evaluated in vitro. In immunohistochemical analysis, repeated cisplatin treatment induced downregulation of HtrA2 protein expression, before and after cisplatin-based chemotherapy in SAC. Progression-free survival and overall survival of SAC with low expression of HtrA2 were worse than those with high expression. In vitro analysis using cisplatin-sensitive ovarian cancer cell lines, KF28, and cisplatin-resistant cancer cell lines, KFr13, obtained from KF28 by repeated cisplatin treatment, showed that HtrA2 protein expression was lower in KFr13 than in KF28. Furthermore, KFr13 had a higher invasive capacity than KF28. Next, downregulation of HtrA2 transfected with an HtrA2-specific siRNA in KF28 had not only cisplatin resistance, but also more invasive capacity than those with non-specific siRNA. Repeated treatment with cisplatin downregulated the HtrA2 protein, which led to cisplatin resistance and increased invasive capacity. Thus, HtrA2 might be a biomarker of response to cisplatin treatment and prognosis, after cisplatin-based chemotherapy.
- 22 November 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (12) , 201
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin
High-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed. The association between the change in HtrA2 and proteins associated with LATS1 in ovarian serous cancer cell lines after repeated treatment with cisplatin was evaluated in vitro. In immunohistochemical analysis, repeated cisplatin treatment induced downregulation of HtrA2 protein expression, before and after cisplatin-based chemotherapy in SAC. Progression-free survival and overall survival of SAC with low expression of HtrA2 were worse than those with high expression. In vitro analysis using cisplatin-sensitive ovarian cancer cell lines, KF28, and cisplatin-resistant cancer cell lines, KFr13, obtained from KF28 by repeated cisplatin treatment, showed that HtrA2 protein expression was lower in KFr13 than in KF28. Furthermore, KFr13 had a higher invasive capacity than KF28. Next, downregulation of HtrA2 transfected with an HtrA2-specific siRNA in KF28 had not only cisplatin resistance, but also more invasive capacity than those with non-specific siRNA. Repeated treatment with cisplatin downregulated the HtrA2 protein, which led to cisplatin resistance and increased invasive capacity. Thus, HtrA2 might be a biomarker of response to cisplatin treatment and prognosis, after cisplatin-based chemotherapy.
- 9 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 111-117
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review
We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype.
- 9 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 111-117
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review
We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype.